NUVATION BIO INC.

(NUVB)
  Report
Delayed Nyse  -  04:00 2022-08-09 pm EDT
2.590 USD   -1.89%
08/04NUVATION BIO : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04NUVATION BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
08/04Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nuvation Bio Study of Lead Product Candidate Put on Partial Clinical Hold by FDA

06/27/2022 | 06:00am EDT

By Dean Seal


Nuvation Bio Inc. said Monday that the Food and Drug Administration has put a partial clinical hold on the Phase 1 dose escalation study of its drug candidate NUV-422.

The New York-based biopharmaceutical company said the trial aims to define the maximum tolerated dose for NUV-422 as a treatment for solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.

The trial started enrolling patients 19 months ago, but following the emergence of a form of eye inflammation in certain patients, Nuvation paused enrollment and reached out to the FDA for guidance, the company said.

While the partial hold is in place, no new patients will be enrolled, though current participants may continue to be treated under the study, Nuvation said.

Share of Nuvation Bio fell 17% in premarket trading to $3.48.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

06-27-22 0800ET

All news about NUVATION BIO INC.
08/04NUVATION BIO : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04NUVATION BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update ..
PU
08/04Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
BU
08/04Nuvation Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended ..
CI
08/02BTIG Downgrades Nuvation Bio to Neutral From Buy
MT
08/02BMO Capital Lowers Nuvation Bio to Market Perform From Outperform, Price Target to $2.5..
MT
08/01SECTOR UPDATE : Health Care Stocks Still Struggling Ahead of Market Close Monday
MT
08/01Wedbush Adjusts Price Target for Nuvation Bio to $5 From $17 on Discontinuation of NUV-..
MT
08/01Nuvation Bio to Discontinue Clinical Study of NUV-422 in Solid Tumors Following Clinica..
MT
08/01SECTOR UPDATE : Health Care Stocks Retreat Fractionally in Early Afternoon Trading
MT
More news
Analyst Recommendations on NUVATION BIO INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -117 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,74x
Yield 2022 -
Capitalization 565 M 565 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 85
Free-Float 71,9%
Chart NUVATION BIO INC.
Duration : Period :
Nuvation Bio Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUVATION BIO INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 2,59 $
Average target price 6,50 $
Spread / Average Target 151%
EPS Revisions
Managers and Directors
David T. Hung President, CEO & Director
Jennifer Fox Chief Financial Officer
Daniel G. Welch Chairman
Gary Hattersley Chief Scientific Officer
Dong Fang Liu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NUVATION BIO INC.-69.53%576
MODERNA, INC.-26.44%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-16.80%43 579
SEAGEN INC.13.72%32 890
ALNYLAM PHARMACEUTICALS, INC.28.89%27 695